Restoration of immune-mediated sensorineural hearing loss with sodium enoxaparin: a case report.
The aim of the study was to assess the efficacy of sodium enoxaparin in the treatment of autoimmune sensorineural hearing loss. A small number of patients with unilateral sensorineural hearing loss were selected and divided randomly into two numerically equal groups (groups A and B) if they fulfilled the inclusion criteria, i.e. being between 20 and 65 years of age, had been affected by systemic lupus erythematosus, had presented with a hearing loss of at least 30 dB of audibility threshold involving the medium frequencies (2000-4000 Hz), and had provided informed consent. Group A received sodium enoxaparin while group B (control) received placebo. In group A, all patients except one showed an improvement in hearing after sodium enoxaparin treatment. In group B, no patients showed an improvement in auditory function. In conclusion, our results underline the important role of sodium enoxaparin in the therapeutic management of this disease. The low number of patients suggests that further studies are required to confirm this initial data but this study suggests that sodium enoxaparin provides encouraging results in the treatment of autoimmune sensorineural hearing loss.
Mora
R
R
ENT Department, University of Genoa, Genoa, Italy. renzomora@libero.it
Mora
F
F
Passali
F M
FM
Cordone
M P
MP
Crippa
B
B
Barbieri
M
M
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001299:Audiometry; D001327:Autoimmune Diseases / Q000188:drug therapy*; D017984:Enoxaparin / Q000627:therapeutic use*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects; D014012:Tinnitus / Q000188:drug therapy; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin